bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 239,800 shares, an increase of 107.6% from the February 28th total of 115,500 shares. Based on an average trading volume of 261,100 shares, the short-interest ratio is currently 0.9 days. Approximately 2.6% of the company’s stock are sold short.

Hedge Funds Weigh In On bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC lifted its holdings in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,304 shares of the company’s stock after purchasing an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Trading Down 4.8 %

NASDAQ BIAF opened at $0.27 on Friday. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a 1-year low of $0.25 and a 1-year high of $3.16. The firm’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $1.09. The company has a market capitalization of $4.22 million, a PE ratio of -0.33 and a beta of 3.12.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.